We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative conditions and other diseases. We leverage our proprietary technology platform called TORPEDO (Target ORiented ProtEin Degrader Optimizer) to synthesize a new class of small molecule protein degraders that are designed to selectively and efficiently destroy disease-causing proteins, including targets previously considered to be undruggable.

We are using our TORPEDO platform to build a robust pipeline of oral protein degradation drug candidates, with our lead product candidates focused on oncology indications. One of our lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, or MM; peripheral T-cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL.